Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcellx, Inc.ACLX · Entity 15294 | Director | February 08, 2022 | February 09, 2022 |
| FIVE PRIME THERAPEUTICS, INC.FPRX · Entity 16595 | Director | September 01, 2019 | September 04, 2019 |
| Neurogene Inc.NLTX · Entity 5160 | Director | May 11, 2021 | May 13, 2021 |
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Director | February 17, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcellx, Inc.
Report date February 08, 2022 · Filed February 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,095,114 |
Reported balance
After 2022-02-08 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-02-08 · Conversion · Acquired 2,095,114 · Balance 2,095,114 F1: All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date. F2: Shares directly held by Quan Venture Fund II, L.P. The general partner of Quan Capital is Quan Venture Partners II, L.L.C. The Reporting Person, a member of the Issuer's board of directors, is a venture partner at Quan Venture Partners II, L.L.C. and, therefore, may be deemed to have a pecuniary interest over these shares. The Reporting Person disclaims beneficial ownership of the shares held of record by Quan Venture Fund II, L.P. except to the extent of his pecuniary interest therein. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2022-02-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-08 · Conversion · Disposed 1,163,886 · Balance 0 F1: All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date. F2: Shares directly held by Quan Venture Fund II, L.P. The general partner of Quan Capital is Quan Venture Partners II, L.L.C. The Reporting Person, a member of the Issuer's board of directors, is a venture partner at Quan Venture Partners II, L.L.C. and, therefore, may be deemed to have a pecuniary interest over these shares. The Reporting Person disclaims beneficial ownership of the shares held of record by Quan Venture Fund II, L.P. except to the extent of his pecuniary interest therein. |
| Series B-2 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2022-02-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-02-08 · Conversion · Disposed 931,228 · Balance 0 F1: All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date. F2: Shares directly held by Quan Venture Fund II, L.P. The general partner of Quan Capital is Quan Venture Partners II, L.L.C. The Reporting Person, a member of the Issuer's board of directors, is a venture partner at Quan Venture Partners II, L.L.C. and, therefore, may be deemed to have a pecuniary interest over these shares. The Reporting Person disclaims beneficial ownership of the shares held of record by Quan Venture Fund II, L.P. except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date.
F2: Shares directly held by Quan Venture Fund II, L.P. The general partner of Quan Capital is Quan Venture Partners II, L.L.C. The Reporting Person, a member of the Issuer's board of directors, is a venture partner at Quan Venture Partners II, L.L.C. and, therefore, may be deemed to have a pecuniary interest over these shares. The Reporting Person disclaims beneficial ownership of the shares held of record by Quan Venture Fund II, L.P. except to the extent of his pecuniary interest therein.
FIVE PRIME THERAPEUTICS, INC.
Report date September 01, 2019 · Filed September 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 455,336 |
Reported balance
After 2019-09-01 transaction · row 1
1 source rowRow 1 · 2019-09-01 · Tax withholding · Disposed 7,024 · Balance 455,336 |
Neurogene Inc.
Report date May 11, 2021 · Filed May 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2031-05-10 | Direct | 25,000 |
Reported balance
After 2021-05-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-11 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests as to 1/12 of the total shares monthly beginning June 11, 2021 until the option is fully vested on May 11, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/12 of the total shares monthly beginning June 11, 2021 until the option is fully vested on May 11, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Protagonist Therapeutics, Inc
Report date February 17, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,825 |
Ending reported balance
After 2026-02-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-17 · Exercise / conversion · Acquired 18,000 · Balance 25,825 Row 2 · 2026-02-17 · Sale · Disposed 18,000 · Balance 7,825 F1: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $81.47 to $83.12. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.84 · Expires 2027-06-15 | Direct | 6,000 |
Reported balance
After 2026-02-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-17 · Exercise / conversion · Acquired 18,000 · Balance 6,000 F2: These stock options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $81.47 to $83.12. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2: These stock options are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2016 Filed Feb 13, 2018 11:46 UTC Amendment | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GiftCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009449 · doc4a.xml · nonDerivative · entry 1 Williams Lewis T · CIK 0001475714 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,827 F1 · shares: This amendment is being filed to reflect that a gift of 22,416 shares of common stock was inadvertently disclosed in the original Form 4 filed with the Securities and Exchange Commission (the "SEC") on February 9, 2017. This gift was already reported in a Form 4 filed with the SEC on September 1, 2016 and as such, the original Form 4 filed on February 9, 2017 should not have included a line item for this gift. This amendment cannot be filed without a completed line item, and as such, this amendment shows that no shares were gifted. Read SEC document |
| September 01, 2016 Filed Feb 13, 2018 11:36 UTC Amendment | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GiftCommon Stock | 22,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009446 · doc4a.xml · nonDerivative · entry 2 Williams Lewis T · CIK 0001475714 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,299 F2 · price: This amendment reflects that the reporting person's gift of 22,416 shares of common stock reported in the original Form 4 filed with the Securities and Exchange Commission on September 1, 2016 was not a market transaction and as such, no price is reported in this amendment. The reporting person did not receive any value for the gifted shares. Read SEC document |
| September 01, 2016 Filed Feb 13, 2018 11:36 UTC Amendment | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Tax withholdingCommon Stock | 32,613 | $44.74 | $1,459,105.62 |
DisclosureSEC source: 0001209191-18-009446 · doc4a.xml · nonDerivative · entry 1 Williams Lewis T · CIK 0001475714 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,715 F1 · shares: This amendment is being filed to reflect the correct disposition of shares of common stock by the reporting person in satisfaction of a tax liability on September 1, 2016. The original Form 4 filed with the Securities and Exchange Commission on September 1, 2016 inadvertently included a disposal of 7,613 shares of common stock rather than 32,613 shares of common stock, as shown in this amendment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.